论文部分内容阅读
本文对2001-2004年间,全印度2816例复治失败结核病患者的痰培养和药物敏感试验结果,在Chennai的结核病研究中心进行了回顾性分析。其中1498例(53%)被确诊为患有耐多药结核病(MDR-TB),671例(44.8%)至少耐一种二线抗结核药,分别为:490例(32.7%)耐乙硫异烟胺,245例(16.4%)耐氧氟沙星,169例(11.3%)耐卡那霉素;69例(4.6%)为广泛耐药结核病(XDR-TB)。尽管本结果是从高度选择的、不具代表性的患者人群中获得,但耐多药结核病患者中的二线抗结核药耐药率(包括XDR率)如此之高仍值得关注。因此,以高质量的DOTS服务来预防M/XDR-TB的产生,仍是目前的首要任务。此外,也需要尽快扩展在修改后的国家结核病控制规划(RNTCP)下的高质量的规划管理,以及更加规范规划之外对二线抗结核药的使用。
This paper reviews the results of sputum culture and drug susceptibility testing of 2816 patients with failed retreatment TB in India from 2001 to 2004 in a retrospective analysis at the Chennai TB Research Center. Of these, 1498 (53%) were diagnosed with MDR-TB and 671 (44.8%) were resistant to at least one second-line anti-TB drug, 490 and 32.7% Amine, 245 (16.4%) ofloxacin, 169 (11.3%) of kanamycin and 69 (4.6%) of XDR-TB. Although the results are obtained from a highly-selected, non-representative patient population, the high rates of second-line anti-TB drug resistance, including XDR rates, among MDR-TB patients remain cause for concern. Therefore, the prevention of M / XDR-TB production with high-quality DOTS services remains the top priority at this moment. In addition, there is also a need to expeditiously improve the quality of program management under the revised National Tuberculosis Control Program (RNTCP) and the use of second-line anti-TB drugs beyond the more formal program.